FF/UMEC/VI | BUD/FOR | Incremental | |
Outcomes | |||
Predicted cumulative exacerbations | |||
Moderate exacerbations | 5.793 | 5.804 | –0.011 |
Severe exacerbations | 1.422 | 1.434 | –0.012 |
Any moderate and/or severe exacerbation | 7.216 | 7.238 | –0.023 |
Total LYs (discounted) | 9.094 | 8.561 | 0.533 |
Total QALYs (discounted) | 6.638 | 6.132 | 0.506 |
Costs | |||
Maintenance | £7531 | £8495 | –£965 |
Moderate exacerbation | £2459 | £2484 | –£25 |
Severe exacerbation | £6874 | £6974 | –£100 |
Pneumonia | £4261 | £3927 | £334 |
Treatment | £4887 | £3339 | £1549 |
Discontinuation | £404 | £641 | –£237 |
Total costs | £26 416 | £25 860 | £556 |
ICER per LY | £1042 | Referent | |
ICER per QALY | £1098 | Referent |
FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; BUD: budesonide; FOR: formoterol; LY: life year; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio. #: Outcomes and costs observed over the complete period (trial-based and Markov models).